User login
Neither clinical nor subclinical hypothyroidism was associated with mild cognitive impairment in a large, population-based study.
Among almost 2,000 elderly subjects, mild cognitive impairment (MCI) was present in 16% of those with normal thyroid function, 17% of those with clinical hypothyroidism, and 18% of those with subclinical hypothyroidism, Dr. Ajay K. Parsaik and his colleagues reported in the Dec. 30 issue of JAMA Neurology (doi:10.1001/jamaneurol.2013.5402).
The findings question the usefulness of pursuing thyroid status as a possible contributor to MCI, wrote Dr. Parsaik of the department of psychiatry and behavior sciences, University of Texas Medical School, Houston, and his coauthors.
"Cognitive decline and thyroid dysfunction are common in the elderly, and a widely held view is that hypothyroidism is a reversible risk factor for cognitive impairment, even though several studies have shown no such association. Our population-based findings also argue against an association and suggest that neither clinical nor subclinical hypothyroidism is a risk factor for MCI. .... This raises questions about the need for routine testing of thyroid function as a part of the diagnostic work-up in patients with MCI."
The team examined thyroid function and cognitive status among 1,904 elderly subjects who were included in the Olmsted County (Minn.) health care records database. Most (1,588; 83%) were cognitively normal; 316 had MCI. Those with MCI were older (82 vs. 80 years), less educated (13 vs. 14 years), and more often carriers of the apolipoprotein E4 risk gene (30% vs. 22%).
Medical comorbidities, including hypertension, coronary artery disease, diabetes, stroke, and depression were significantly more common among those with MCI.
Most subjects (1,450) had normal thyroid function. Of these, 84% were cognitively normal and 16% had MCI.
Clinical hypothyroidism was present in 313; of these, 83% were cognitively normal, and 17% had MCI. All subjects were taking thyroid replacement therapy.
Subclinical hypothyroidism was present in 141; of these, 83% were cognitively normal and 18% had MCI. None of these subjects were getting thyroid replacement therapy.
In an analysis that controlled for age, education, sex, APOE E4 status, depression, and medical comorbidities, MCI was not significantly associated with either clinical or subclinical hypothyroidism. There was no significant interaction between APOE E4 status and hypothyroidism.
The authors noted that their findings should be validated in a larger, longitudinal study in a more varied population.
The study was sponsored by the National Institutes of Health. Dr. Parsaik had no financial disclosures. One of the coauthors, Dr. Bradley Boeve, reported multiple disclosures, some with pharmaceutical companies.
Neither clinical nor subclinical hypothyroidism was associated with mild cognitive impairment in a large, population-based study.
Among almost 2,000 elderly subjects, mild cognitive impairment (MCI) was present in 16% of those with normal thyroid function, 17% of those with clinical hypothyroidism, and 18% of those with subclinical hypothyroidism, Dr. Ajay K. Parsaik and his colleagues reported in the Dec. 30 issue of JAMA Neurology (doi:10.1001/jamaneurol.2013.5402).
The findings question the usefulness of pursuing thyroid status as a possible contributor to MCI, wrote Dr. Parsaik of the department of psychiatry and behavior sciences, University of Texas Medical School, Houston, and his coauthors.
"Cognitive decline and thyroid dysfunction are common in the elderly, and a widely held view is that hypothyroidism is a reversible risk factor for cognitive impairment, even though several studies have shown no such association. Our population-based findings also argue against an association and suggest that neither clinical nor subclinical hypothyroidism is a risk factor for MCI. .... This raises questions about the need for routine testing of thyroid function as a part of the diagnostic work-up in patients with MCI."
The team examined thyroid function and cognitive status among 1,904 elderly subjects who were included in the Olmsted County (Minn.) health care records database. Most (1,588; 83%) were cognitively normal; 316 had MCI. Those with MCI were older (82 vs. 80 years), less educated (13 vs. 14 years), and more often carriers of the apolipoprotein E4 risk gene (30% vs. 22%).
Medical comorbidities, including hypertension, coronary artery disease, diabetes, stroke, and depression were significantly more common among those with MCI.
Most subjects (1,450) had normal thyroid function. Of these, 84% were cognitively normal and 16% had MCI.
Clinical hypothyroidism was present in 313; of these, 83% were cognitively normal, and 17% had MCI. All subjects were taking thyroid replacement therapy.
Subclinical hypothyroidism was present in 141; of these, 83% were cognitively normal and 18% had MCI. None of these subjects were getting thyroid replacement therapy.
In an analysis that controlled for age, education, sex, APOE E4 status, depression, and medical comorbidities, MCI was not significantly associated with either clinical or subclinical hypothyroidism. There was no significant interaction between APOE E4 status and hypothyroidism.
The authors noted that their findings should be validated in a larger, longitudinal study in a more varied population.
The study was sponsored by the National Institutes of Health. Dr. Parsaik had no financial disclosures. One of the coauthors, Dr. Bradley Boeve, reported multiple disclosures, some with pharmaceutical companies.
Neither clinical nor subclinical hypothyroidism was associated with mild cognitive impairment in a large, population-based study.
Among almost 2,000 elderly subjects, mild cognitive impairment (MCI) was present in 16% of those with normal thyroid function, 17% of those with clinical hypothyroidism, and 18% of those with subclinical hypothyroidism, Dr. Ajay K. Parsaik and his colleagues reported in the Dec. 30 issue of JAMA Neurology (doi:10.1001/jamaneurol.2013.5402).
The findings question the usefulness of pursuing thyroid status as a possible contributor to MCI, wrote Dr. Parsaik of the department of psychiatry and behavior sciences, University of Texas Medical School, Houston, and his coauthors.
"Cognitive decline and thyroid dysfunction are common in the elderly, and a widely held view is that hypothyroidism is a reversible risk factor for cognitive impairment, even though several studies have shown no such association. Our population-based findings also argue against an association and suggest that neither clinical nor subclinical hypothyroidism is a risk factor for MCI. .... This raises questions about the need for routine testing of thyroid function as a part of the diagnostic work-up in patients with MCI."
The team examined thyroid function and cognitive status among 1,904 elderly subjects who were included in the Olmsted County (Minn.) health care records database. Most (1,588; 83%) were cognitively normal; 316 had MCI. Those with MCI were older (82 vs. 80 years), less educated (13 vs. 14 years), and more often carriers of the apolipoprotein E4 risk gene (30% vs. 22%).
Medical comorbidities, including hypertension, coronary artery disease, diabetes, stroke, and depression were significantly more common among those with MCI.
Most subjects (1,450) had normal thyroid function. Of these, 84% were cognitively normal and 16% had MCI.
Clinical hypothyroidism was present in 313; of these, 83% were cognitively normal, and 17% had MCI. All subjects were taking thyroid replacement therapy.
Subclinical hypothyroidism was present in 141; of these, 83% were cognitively normal and 18% had MCI. None of these subjects were getting thyroid replacement therapy.
In an analysis that controlled for age, education, sex, APOE E4 status, depression, and medical comorbidities, MCI was not significantly associated with either clinical or subclinical hypothyroidism. There was no significant interaction between APOE E4 status and hypothyroidism.
The authors noted that their findings should be validated in a larger, longitudinal study in a more varied population.
The study was sponsored by the National Institutes of Health. Dr. Parsaik had no financial disclosures. One of the coauthors, Dr. Bradley Boeve, reported multiple disclosures, some with pharmaceutical companies.
Major finding: The incidence of MCI was similar in patients with clinical hypothyroidism (17%), subclinical hypothyroidism (18%), and normal thyroid function (16%).
Data source: The population-based study included 1,904 subjects.
Disclosures: The study was sponsored by the National Institutes of Health. Dr. Parsaik had no financial disclosures One of the coauthors, Dr. Bradley Boeve, reported multiple disclosures, some with pharmaceutical companies.